Blue Earth Therapeutics Announces Publication of Results from Independent Clinical Experience with 177Lu-rhPSMA-10.1 in Treatment of Metastatic Castrate Resistant Prostate Cancer

First reported clinical results from independent clinical experience by University of Augsburg demonstrated encouraging preliminary data for 177Lu-rhPSMA-10.1

Related Keywords

United States ,Germany ,German ,Constantin Lapa ,David Gauden ,Department Of Nuclear Medicine ,University Hospital Augsburg ,Journal Of Nuclear Medicine ,Drug Administration ,University Hospital ,Blue Earth Therapeutics ,Efficacy Data ,Metastatic Prostate Cancer ,Nuclear Medicine ,Prostate Specific Membrane Antigen Targeted ,Blue Earth Therapeutic ,Therapeutic Index ,Chief Executive Officer ,Blue Earth ,